Jacqueline V. Aredo

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 166 citations · Full text

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

Jacqueline V. Aredo, Sukhmani K. Padda, Christian A. Kunder et al. · Lung Cancer · 2019 · 127 citations · Full text

Somatic Variant, Tumor Heterogeneity, Medicine +11

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer et al. · Journal of Thoracic Oncology · 2021 · 126 citations · Full text

Medicine, Cancer Treatment, Oncology +3

Risk Model–Based Lung Cancer Screening and Racial and Ethnic Disparities in the US

Eunji Choi, Victoria Y. Ding, Sophia J. Luo et al. · JAMA Oncology · 2023 · 60 citations · Full text

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC

Jessica A. Hellyer, Jacqueline V. Aredo, Millie Das et al. · Journal of Thoracic Oncology · 2021 · 57 citations · Full text

Consolidation Durvalumab, Medicine, Pathology +6